The Allele Frequency of EGFR Mutations Predicts Survival in Advanced EGFR T790M-Positive Non-small Cell Lung Cancer Patients Treated with Osimertinib.

Target Oncol · 2021 · PMC7810636 · PMID 33270169

Europe PMC DOI

hedged sentence

0.1100

closest p · 2.2× alpha

0.1100

boldest claim

The sentences

showed a trendP = 0.11not close (p > 0.1)

1 e) and showed a trend towards a shorter OS (median 10.4 months vs 16.6 months, P = 0.11) (Fig. 1 f) than patients with a value of > 0.22.

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.